Umbilical cord cells for kidney transplant rejection
Part of Blood & lymphatic, Immune system & allergy, Kidney & urinary clinical trials.
This trial tests whether giving a special type of umbilical cord cell can help treat a form of kidney rejection that hasn't improved with standard antibody treatment. It aims to slow down or stop further kidney damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had a kidney transplant.
- You have been diagnosed with chronic antibody-mediated rejection (kidney injury caused by antibodies) in the last 6 months.
- Your kidney function is above a certain level (eGFR greater than 30).
- You have high levels of protein in your urine (a sign of kidney damage).
- You are able to attend follow-up visits and give written consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether belatacept can help prevent damage in kidney transplant recipients who develop new antibodies against their donor kidney. It is for people whose kidney function is still stable, which may allow treatment to slow or stop antibody-related injury.
This study tests an experimental drug called CID-103 to treat antibody-mediated rejection (ABMR), a type of immune response that damages transplanted kidneys. The drug targets immune cells that attack the transplant, and researchers hope it may help preserve kidney function and prevent transplant failure.
This study tests a new combination of drugs (an antibody called CD38 mAb plus azathioprine) to treat a type of chronic rejection that can happen months or years after a kidney transplant. The goal is to see if it can help stabilize or improve kidney function and prevent further damage.
This study looks at tissue samples from kidney transplant patients who have a specific type of long-term rejection called chronic active humoral rejection (cAMR). It aims to better understand the condition and help future patients.
This study tests a new treatment called BiTE (a type of immunotherapy that helps your immune cells attack harmful antibodies) for people whose transplanted kidney is being damaged by chronic active antibody-mediated rejection. The goal is to see if it can safely slow or stop this damage.
This study tests whether a treatment made from stem cells can help people who have a specific kind of kidney transplant rejection that happens over time. The goal is to see if it can stop the rejection and help keep the kidney working longer.
Hear when a new Chronic Antibody-mediated Rejection (cABMR) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.